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The goal of anesthesia is to erase the reality of the surgical insult andto restore patients as quickly as possible to their premorbid state. Thesafest and most cost-effective anesthetic technique with the greatestsalutary effect on cardiac surgical outcome is a subject of currentdebate. Economic and social realities have rendered the hemody-namically stable, high-dose, narcotic-based anesthetic technique pi-
oneered by Edward Lowenstein in the early 1970s fiscally prohibitive. In addition,
societal expectations for minimally invasive surgery and rapid recovery fuel the
growth and ubiquity of fast-track anesthesia for all but the most critical of patients.
As a result, shorter-acting anesthetic agents are currently used to restore conscious-
ness and spontaneous unassisted ventilation within hours of termination of the
cardiac surgical procedure. With the line between anesthetics for cardiac surgery
and anesthetics for other major surgical procedures becoming increasingly faint, the
importance of pain control in the early postoperative period is emerging.
The natural history of pain after cardiac surgery remains inadequately described
and traditionally dismissed as of minor clinical consequence. Undoubtedly, this
perception has evolved from the long history of prolonging general anesthesia into
the postoperative period, a practice that is now no longer economically viable. Pain
and the ensuing stress response are being increasingly recognized for their contrib-
utory role in postoperative complications and their profound cumulative economic
effect.1 Yet the majority of cardiac intensive care units in the United States still
adhere to the antiquated, highly subjective, and inefficient paradigm of intravenous,
nurse-administered postoperative analgesia. Few of the regional anesthetic tech-
niques (spinal, epidural, and nerve block) or supplementary adjuvants (nonsteroidal
anti-inflammatories and patient-controlled analgesia) widely used in the general
surgical population to attenuate postoperative pain have been adopted into main-
stream cardiac care. Thus the sophistication, technologic advancements, and cus-
tomization of postoperative pain management seem to have bypassed one of the
largest surgical populations in the world today. This situation requires change.
This month’s featured article entitled “Improved pain control after cardiac
surgery,” coauthored by the surgeon-anesthesiologist team of Robert Dowling,
Kenneth Thielmeier, and their associates, emphasizes the need for change and
underscores the potential positive consequences that attenuation of pain after cardiac
surgery might have on outcome, cost, and patient satisfaction.2 This very small (n
 35 patients) prospective, randomized, blinded, placebo-controlled trial examining
intraoperative bilateral intercostal nerve block (and continuous subcutaneous infu-
sion) with either local anesthetic (ropivacaine) or placebo after median sternotomy
not surprisingly reveals decreased postoperative consumption of intravenous nar-
cotics and significantly lower visual analog pain scores in patients receiving the
local anesthetic. More notably, the authors also demonstrate a shorter hospital length
of stay in the treatment group and estimate the potential annual national cost
implication at approximately 1.4 billion dollars. However, the attempt to link
improved pain control with better clinical outcome was unsuccessful. A likely
explanation for the acceptance of the null hypothesis might be attributable to the
small sample size, the relatively healthy patient population studied, and the rela-
tively crude respiratory and cardiac end points chosen to investigate. However, this
study is important because it focuses our attention on an underappreciated, inade-
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quately studied, and poorly understood aspect of cardiac
surgical recovery that, if better understood, might be ma-
nipulated to improve morbidity and decrease cost.
The Pain Prism
Pain is defined as “an unpleasant sensory and emotional
experience associated with actual or potential tissue dam-
age.” The surgical insult of cardiac surgery can be concep-
tually divided into 2 main components: that associated with
tissue trauma/pain and that associated with the sequelae of
cardiopulmonary bypass (CPB). Acute postoperative pain
from required surgical exposure is primarily inflammatory
in nature, associated with release of chemical mediators,
and possibly modified in perception and expression by
psychologic and social factors. Classically, the intensity of
pain is commensurate with the extent and the location of the
soft tissue destruction (with small peripheral incisions elic-
iting less response in comparison with large central inci-
sions). The degree to which the tissue trauma of sternotomy,
with pericardial entry and cardiac manipulation, contributes
to the total stress response exhibited by patients undergoing
cardiac surgery has not been fully elucidated. It has been
known for many years that CPB induces a wide variety of
physiologic changes that could be detrimental to patients
undergoing cardiac surgery. There is a plethora of validated
evidence indicating that the intensity of this stress response
during cardiac surgery greatly exceeds that of most other
surgical procedures. Studies further suggest that the inten-
sity of this stress response during off-pump coronary revas-
cularization (OPCAB) is less profound when compared with
that after similar surgery with the assistance of CPB, yet the
presence of significant amounts of inflammatory markers
even after OPCAB intimates that CPB is not the solitary
source of postoperative stress. Because of the complexity,
interdependency, and overlap of these inflammatory path-
ways (both pain-related and procedure-related pathways),
the teasing out of the precise relative contribution of pain
versus procedure to the entire postoperative stress response
is difficult.
All types of anesthesia (general or regional) seek to
eliminate both components of the surgical injury. General
anesthesia remains the predominant technique for patients
undergoing cardiac surgery and, by definition, provides
analgesia, amnesia-hypnosis, and muscle relaxation, which
are necessary for the procedure. Although it is technically
feasible to perform coronary surgery through a median
sternotomy with regional anesthesia alone,3 adequate spon-
taneous ventilation after mediastinal entry, thoracic entry, or
both limits the adoption of this technique to only the health-
iest of patients undergoing OPCAB.
Accepting the premise that general anesthesia with me-
chanical ventilation is necessary for the safe execution of
cardiac surgery, then the ideal anesthetic would comprise
the following features: complete intraoperative and postop-
erative elimination of the pain-mediated stress response,
attenuation of the stress response to CPB, and quick return
of adequate, unassisted, homeostatic bodily functions (eg,
respiration, circulation, and cognitive function) at the ter-
mination of the surgical procedure. Unfortunately, the ces-
sation of general anesthesia soon after surgical intervention
requires the withdrawal of intravenous and inhalation
agents, rendering the patient at risk for pain and its detri-
mental consequences on respiration and hemodynamics.
The Case Against Pain
Inadequate analgesia, an uninhibited stress response, or both
during the postoperative period could lead to many adverse
hemodynamic (tachycardia, hypertension, and vasoconstric-
tion), metabolic (increased catabolism), immunologic (im-
paired immune response), and hemostatic (platelet activa-
tion) alterations. In patients undergoing cardiac surgery,
perioperative myocardial ischemia is most commonly ob-
served during the immediate postoperative period and is
related to outcome. As previously stated, numerous intra-
operative factors (including CPB) stimulate significant in-
creases in stress response hormones (eg, norepinephrine and
epinephrine) that persist into the immediate postoperative
period and might contribute to myocardial ischemia ob-
served during this time. Furthermore, postoperative myo-
cardial ischemia could be aggravated by cardiac sympa-
thetic nerve activation, which disrupts the balance between
coronary blood flow and myocardial oxygen demand. Ag-
gressive control of postoperative pain with intravenous an-
algesics in patients after cardiac surgery could potentially
decrease morbidity and mortality.4,5 In adults undergoing
cardiac surgery, intense analgesia (continuous intravenous
opioid infusion) during the immediate postoperative period
(first 18 hours) decreases the incidence and severity of
myocardial ischemia, as diagnosed by means of electrocar-
diography.4 In neonates undergoing cardiac surgery, intense
analgesia (continuous intravenous opioid infusion) during
the immediate postoperative period (first 24 hours) de-
creases morbidity and mortality.5 Unfortunately, aggressive
control of pain with intravenous opioids in this manner does
not allow tracheal extubation to occur in the immediate
postoperative period.
Regional Anesthetic Techniques
Although use of specific nerve blocks has been sporadically
investigated, most attempts at regional anesthesia supple-
mentation in patients undergoing cardiac surgery have in-
volved spinal intrathecal techniques, epidural techniques, or
both. Intrathecal or epidural application of opioids, local
anesthetics, or both are attractive alternatives to intravenous
opioids in this setting for their potential to produce intense
analgesia yet still allow extubation to occur in the immedi-
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ate postoperative period.6 In addition to producing intense
postoperative analgesia, perioperative use of intrathecal or
epidural techniques in patients undergoing cardiac surgery
might also beneficially affect outcome through stress re-
sponse attenuation (not related to analgesia) and induction
of thoracic cardiac sympathectomy.6
Intrathecal and epidural local anesthetics appear to pos-
sess greater efficacy than opioids (administered similarly) in
stress response attenuation, perhaps because of their unique
mechanism of action, which also contributes to the hypo-
tension associated with their use. Local anesthetics effec-
tively block cardiac sympathetic nerve afferent and efferent
fibers, whereas opioids (administered similarly) are unable
to do so. In short, application of local anesthetics might
benefit patients undergoing cardiac surgery by effectively
blocking cardiac sympathetic nerve activity and improving
myocardial oxygen supply-demand balance through numer-
ous mechanisms.
Well-controlled clinical investigations attest to the abil-
ity of intrathecal opioids to reliably induce intense postop-
erative analgesia in patients after cardiac surgery.7,8 Al-
though use of intrathecal local anesthetics has been
investigated, the hemodynamic changes associated with a
total spinal make the technique unpalatable to most anes-
thesiologists. Because of enhanced flexibility, most recent
clinical investigations have focused on use of thoracic epi-
dural techniques in patients undergoing cardiac surgery. In
contrast to intrathecal techniques (single shot of a drug), the
presence of a catheter in the epidural space allows an almost
infinite number of possibilities regarding potential drugs
(opioids, local anesthetics, or both) and dosing schedules to
attain intense postoperative analgesia, stress response atten-
uation, and/or thoracic cardiac sympathectomy. Administra-
tion of epidural local anesthetics (not opioids) can both
reliably attenuate the stress response associated with the
immediate postoperative period and induce thoracic cardiac
sympathectomy. Suggested clinical benefits of either the
intrathecal or epidural technique include enhanced postop-
erative analgesia, improved postoperative pulmonary func-
tion, facilitation of early extubation, improved myocardial
protection, decreased postoperative arrhythmias, improved
postoperative renal function, and decreased postoperative
confusion.9-11
One must keep in mind, however, that using intrathecal
techniques, epidural techniques, or both in patients under-
going cardiac surgery entails risk. The most troubling and
undesirable drug effect of intrathecal or epidural local an-
esthetics is hypotension. Although many have been de-
scribed, the four clinically relevant undesirable drug effects
of intrathecal and epidural opioids are pruritus, nausea and
vomiting, urinary retention, and respiratory depression. Ex-
cessive respiratory depression might delay tracheal extuba-
tion. The most feared complication of intrathecal and epi-
dural instrumentation is hematoma formation. Substantial
controversy exists regarding the safety of intrathecal instru-
mentation, epidural instrumentation, or both in patients who
will subsequently receive anticoagulation. Substantial con-
troversy also exists regarding whether intrathecal and epi-
dural techniques truly affect morbidity and mortality in
patients undergoing cardiac surgery. Essentially, all reports
of intrathecal and epidural techniques in patients undergo-
ing cardiac surgery involve small numbers of patients, and
few (if any) are well designed. Furthermore, most investi-
gations do not use clinical outcome as a primary end point.
Thus there are clear deficiencies in the literature that pro-
hibit definitive analysis of the risk/benefit ratio of intrathe-
cal and epidural techniques in patients undergoing cardiac
surgery.
Intercostal nerve block, as described in the current arti-
cle, has been used extensively and effectively for blunting
pain associated with thoracotomy, as well as with chest tube
insertion. However, its use as an analgesic adjunct after
median sternotomy is less common. The analgesic effect of
single-shot intercostal nerve block with ropivacaine is tran-
sient, with a duration of action of less than 4 hours. The
subcutaneous continuous infusion used in this study, admin-
istered through a catheter positioned anterior to the sternal
wires, presumably bathes the anterior cutaneous branches of
the intercostal nerves at multiple levels, thereby providing a
longer-acting analgesic effect. It is important to note that
systemic absorption of local anesthetic from an intercostal
nerve block is substantial and rapid (when compared with
other anatomic sites). Although increased plasma concen-
trations of local anesthetic are necessary to produce cardiac
and neurologic toxicity (ventricular arrhythmia and sei-
zures), such potentially lethal complications should always
be considered and total drug dosages adjusted accordingly
on the basis of appropriate factors (eg, specific local anes-
thetic, site of injection, and body weight).
The Future: Multimodal Anesthesia?
In this era of challenge and great uncertainty for the noble
specialty of cardiothoracic surgery, this investigation by
Dowling and associates2 is notable for its distinctly nonsur-
gical focus. Although not providing definitive data and
proof, their small clinical investigation indicates that what
most of us intuitively believe might be true: that the quality
of postoperative pain control is likely linked to morbidity
(and thus linked to cost). If one were to try to predict the
future, the next step to the management of postoperative
pain most likely lies in the synthesis of multiple techniques,
each inadequate in itself, but when used together exhibiting
a significant effect with a much attenuated risk profile.
Further study is needed to solidify the link between pain and
morbidity and to better quantify the risks of the neuraxial
anesthetic techniques in our surgical population. We hope
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that such investigation heralds the beginning of a culture
change toward a patient-centered approach to cardiac sur-
gical interventions and investigations (involving surgeons
and anesthesiologists) in which the patient’s experience is
inextricably linked to the definition of quality care and
outcome.
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